1. Home
  2. Disease & Disorders
  3. Centerville, OH
  4. Dayton Clinical Oncology Program

Dayton Clinical Oncology Program

Dayton Clinical Oncology Program is ranked among disease & disorders organizations in Centerville, OH, with an America's Best Score of 69 out of 100, based on its 2025 Form 990.

  • Centerville, OH
  • Tax-exempt since 1984
  • EIN: 31-1100389
daytonncorp.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
69OF 100 Ranked in Centerville Disease & Disorders How this score is calculated

Organization summary

Dayton Clinical Oncology Program is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G30Z). Contributions are tax-deductible.

6480 Centerville Business Pkwy, Centerville, OH 45459-2633

In fiscal year 2025 it reported $974,625 in revenue and $1,138,634 in expenses, with contributions making up 88.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

To reduce cancer incidence and mortality through improved treatment and prevention by offering national, state-of-the-art cancer research to local communities.

Main program · fiscal year 2025

  • Dayton Clinical Oncology Program, incorporated in 1983, was designated one of the original national cancer institute (nci) grant-funded community clinical oncology programs. Its mission is to provide access to state-of-the-art nci clinical trials to communities throughout Ohio and eastern Indiana. Membership within the nci network provides access to phase II and phase III trials for newly diagnose… Read more

    Dayton Clinical Oncology Program, incorporated in 1983, was designated one of the original national cancer institute (nci) grant-funded community clinical oncology programs. Its mission is to provide access to state-of-the-art nci clinical trials to communities throughout Ohio and eastern Indiana. Membership within the nci network provides access to phase II and phase III trials for newly diagnosed as well as advanced cancer patients, with options for treatment, symptom management, cancer care delivery, and demographic trials. The collaboration between Dayton Clinical Oncology Program and its consortium members of eight hospitals, 48 physicians representing medical, surgical and radiation oncology, and hospital-based oncology research coordinators is what makes the program successful and available for cancer patients.

    $1,024,770 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 90¢ went to programs, 10¢ to management and 0¢ to fundraising.

  • Programs $1,024,770
  • Management $112,973
  • Fundraising $891

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score69 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves26.5 mo; 1.0 mo in cash18.4 / 25
Financial balance (median margin)−9.4%3.9 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+0.7% / yr7.8 / 15
Track record42 years10 / 10
Debt load15.1% of assets9 / 10
Total69.1 → 69
Spending on programs
Not scored; America's Best needs 65%+
90%Meets

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$974,625Fiscal year 20252022: $1,120,83920222023: $1,111,95620232024: $1,029,62120242025: $974,6252025
Expenses$1,138,634Fiscal year 20252022: $1,115,57820222023: $1,221,21420232024: $1,142,43520242025: $1,138,6342025
Total assets$2,961,723Fiscal year 20252022: $2,853,57720222023: $3,198,69720232024: $3,080,79020242025: $2,961,7232025
Total liabilities$447,655Fiscal year 20252022: $44,56520222023: $564,48120232024: $475,77020242025: $447,6552025
Fiscal year ending May 2025
Revenue$974,625
Expenses$1,138,634
Net income−$164,009
Net assets$2,514,068

Notable sources of revenue

Percent of total revenue
Contributions$857,551
Program services$49,361
Investment income$62,911
Other (net)$4,802

Assets / debt

Total assets$2,961,723
Total liabilities$447,655
Net assets$2,514,068

Compensation

Not in our extract for this year.

Fiscal year ending May 2024
Revenue$1,029,621
Expenses$1,142,435
Net income−$112,814
Net assets$2,605,020

Notable sources of revenue

Percent of total revenue
Contributions$948,944
Program services$36,513
Investment income$43,177
Other (net)$987

Assets / debt

Total assets$3,080,790
Total liabilities$475,770
Net assets$2,605,020

Compensation

Not in our extract for this year.

Fiscal year ending May 2023
Revenue$1,111,956
Expenses$1,221,214
Net income−$109,258
Net assets$2,634,216

Notable sources of revenue

Percent of total revenue
Contributions$984,733
Program services$83,169
Investment income$39,850
Other (net)$4,204

Assets / debt

Total assets$3,198,697
Total liabilities$564,481
Net assets$2,634,216

Compensation

Not in our extract for this year.

Fiscal year ending May 2022
Revenue$1,120,839
Expenses$1,115,578
Net income$5,261
Net assets$2,809,012

Notable sources of revenue

Percent of total revenue
Contributions$915,159
Program services$163,147
Investment income$40,857
Other (net)$1,676

Assets / debt

Total assets$2,853,577
Total liabilities$44,565
Net assets$2,809,012

Compensation

Officers and key employees$120,261
Share of expenses10.8%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?